{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:41:17Z","timestamp":1778564477492,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,23]]},"DOI":"10.7759\/cureus.54769","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T16:59:29Z","timestamp":1708707569000},"source":"Crossref","is-referenced-by-count":1,"title":["Assessing the Impact of Comorbid Hypercalcemia on Inpatient Outcomes of Patients With Diffuse Large B-cell Lymphoma During Admission for Chemotherapy"],"prefix":"10.7759","author":[{"given":"Dennis D","family":"Kumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishali","family":"Deenadayalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel M","family":"Odoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badri","family":"Aryal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekrem","family":"Turk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayobami","family":"Olafimihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaldun","family":"Obeidat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Vakil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navika","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Zia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma","volume":"369","author":"Stiff PJ","year":"2013","unstructured":"Stiff PJ, Unger JM, Cook JR, et al.. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013, 369:1681-90. 10.1056\/NEJMoa1301077","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma","volume":"87","author":"Martelli M","year":"2013","unstructured":"Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013, 87:146-71. 10.1016\/j.critrevonc.2012.12.009","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li S","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018, 50:74-87. 10.1016\/j.pathol.2017.09.006","journal-title":"Pathology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3113-z","article-title":"Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement","volume":"17","author":"Lehners N","year":"2017","unstructured":"Lehners N, Kr\u00e4mer I, Saadati M, Benner A, Ho AD, Witzens-Harig M. Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement. BMC Cancer. 2017, 17:128. 10.1186\/s12885-017-3113-z","journal-title":"BMC Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198012113032401","article-title":"Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups","volume":"303","author":"Stewart AF","year":"1980","unstructured":"Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med. 1980, 303:1377-83. 10.1056\/NEJM198012113032401","journal-title":"N Engl J Med"},{"key":"ref6","article-title":"[Cytokines in bone diseases. Cytokines and malignancy-associated hypercalcemia]","volume":"20","author":"Okazaki R","year":"2010","unstructured":"Okazaki R. [Cytokines in bone diseases. Cytokines and malignancy-associated hypercalcemia]. Clin Calcium. 2010, 20:1497-502.","journal-title":"Clin Calcium"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1055\/a-1049-0647","article-title":"Diagnosis, pathophysiology and management of hypercalcemia in malignancy: a review of the literature","volume":"51","author":"Asonitis N","year":"2019","unstructured":"Asonitis N, Angelousi A, Zafeiris C, Lambrou GI, Dontas I, Kassi E. Diagnosis, pathophysiology and management of hypercalcemia in malignancy: a review of the literature. Horm Metab Res. 2019, 51:770-8. 10.1055\/a-1049-0647","journal-title":"Horm Metab Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/ar2168","article-title":"Multiple myeloma\/hypercalcemia","volume":"9 Suppl 1","author":"Oyajobi BO","year":"2007","unstructured":"Oyajobi BO. Multiple myeloma\/hypercalcemia. Arthritis Res Ther. 2007, 9 Suppl 1:S4. 10.1186\/ar2168","journal-title":"Arthritis Res Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S83681","article-title":"Hypercalcemia of malignancy and new treatment options","volume":"11","author":"Sternlicht H","year":"2015","unstructured":"Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag. 2015, 11:1779-88. 10.2147\/TCRM.S83681","journal-title":"Ther Clin Risk Manag"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12923","article-title":"Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies","volume":"99","author":"Zagouri F","year":"2017","unstructured":"Zagouri F, Kastritis E, Zomas A, et al.. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. Eur J Haematol. 2017, 99:409-14. 10.1111\/ejh.12923","journal-title":"Eur J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.55.8.637-a","article-title":"Incidence and prognostic significance of hypercalcaemia in B-cell non-Hodgkin's lymphoma","volume":"55","author":"Majumdar G","year":"2002","unstructured":"Majumdar G. Incidence and prognostic significance of hypercalcaemia in B-cell non-Hodgkin's lymphoma. J Clin Pathol. 2002, 55:637-8. 10.1136\/jcp.55.8.637-a","journal-title":"J Clin Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1620946","article-title":"Prevalence and clinical significance of hypercalcemia at diagnosis in diffuse large B-cell lymphoma","volume":"60","author":"Abadi U","year":"2019","unstructured":"Abadi U, Peled L, Gurion R, Rotman-Pikielny P, Raanani P, Ellis MH, Rozovski U. Prevalence and clinical significance of hypercalcemia at diagnosis in diffuse large B-cell lymphoma. Leuk Lymphoma. 2019, 60:2922-6. 10.1080\/10428194.2019.1620946","journal-title":"Leuk Lymphoma"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2735","article-title":"Hypercalcemia at diagnosis of diffuse large B-cell lymphoma is not uncommon and is associated with high-risk features and a short diagnosis-to-treatment interval","volume":"38","author":"Gauchy AC","year":"2020","unstructured":"Gauchy AC, Kanagaratnam L, Quinquenel A, et al.. Hypercalcemia at diagnosis of diffuse large B-cell lymphoma is not uncommon and is associated with high-risk features and a short diagnosis-to-treatment interval. Hematol Oncol. 2020, 38:326-33. 10.1002\/hon.2735","journal-title":"Hematol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03890-w","article-title":"Hypercalcemia is associated with a poor prognosis in lymphoma a retrospective monocentric matched-control study and extensive review of published reported cases","volume":"99","author":"Vallet N","year":"2020","unstructured":"Vallet N, Ertault M, Delaye JB, et al.. Hypercalcemia is associated with a poor prognosis in lymphoma a retrospective monocentric matched-control study and extensive review of published reported cases. Ann Hematol. 2020, 99:229-39. 10.1007\/s00277-019-03890-w","journal-title":"Ann Hematol"},{"key":"ref15","unstructured":"Healthcare Cost and Utilization Project. Introduction to the HCUP National Inpatient Sample 2017. (2020). Accessed. June 29, 2020: https:\/\/www.hcup-us.ahrq.gov\/db\/nation\/nis\/NIS_Introduction_2017.jsp."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001215)89:12<2667::aid-cncr21>3.0.co;2-p","article-title":"Different age limits for elderly patients with indolent and aggressive non\u2010Hodgkin lymphoma and the role of relative survival with increasing age: analysis of a population\u2010based non\u2010Hodgkin lymphoma registry","volume":"89","author":"Maartense E.","year":"2000","unstructured":"Maartense E., Kluin\u2010Nelemans H. C., le Cessie S., Kluin P. M., Snijder S.,Noordijk E. M.. Different age limits for elderly patients with indolent and aggressive non\u2010Hodgkin lymphoma and the role of relative survival with increasing age: analysis of a population\u2010based non\u2010Hodgkin lymphoma registry. Cancer. 2000, 89:2667-2676. 10.1002\/1097-0142(20001215)89:12&lt;2667::aid-cncr21&gt;3.0.co;2-p","journal-title":"Cancer"},{"key":"ref17","article-title":"Cancer-induced hypercalcemia","volume":"29","author":"Lumachi F","year":"2009","unstructured":"Lumachi F, Brunello A, Roma A, Basso U. Cancer-induced hypercalcemia. Anticancer Res. 2009, 29:1551-5.","journal-title":"Anticancer Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.12.006","article-title":"Mechanisms of hypercalcemia in non-Hodgkin lymphoma and associated outcomes: a retrospective review","volume":"18","author":"Shallis RM","year":"2018","unstructured":"Shallis RM, Rome RS, Reagan JL. Mechanisms of hypercalcemia in non-Hodgkin lymphoma and associated outcomes: a retrospective review. Clin Lymphoma Myeloma Leuk. 2018, 18:e123-9. 10.1016\/j.clml.2017.12.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref19","article-title":"Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas","author":"Seymour JF","year":"1993","unstructured":"Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. 1993."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2023.2204285","article-title":"Impact of protein-energy malnutrition on outcomes of patients with diffuse large B cell lymphoma admitted for inpatient chemotherapy","volume":"36","author":"Deenadayalan V","year":"2023","unstructured":"Deenadayalan V, Olafimihan A, Ganesan V, Kumi D, Zia M. Impact of protein-energy malnutrition on outcomes of patients with diffuse large B cell lymphoma admitted for inpatient chemotherapy. Proc (Bayl Univ Med Cent). 2023, 36:439-42. 10.1080\/08998280.2023.2204285","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","unstructured":"A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993, 329.987-94. 10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00405-7","article-title":"Kidney injury and disease in patients with haematological malignancies","volume":"17","author":"Bridoux F","year":"2021","unstructured":"Bridoux F, Cockwell P, Glezerman I, et al.. Kidney injury and disease in patients with haematological malignancies. Nat Rev Nephrol. 2021, 17:386-401. 10.1038\/s41581-021-00405-7","journal-title":"Nat Rev Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02470312","article-title":"Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia","volume":"7","author":"Rosner MH","year":"2012","unstructured":"Rosner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol. 2012, 7:1722-9. 10.2215\/CJN.02470312","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000086127","article-title":"Vasogenic edema in a case of hypercalcemia-induced posterior reversible encephalopathy","volume":"53","author":"Kim JH","year":"2005","unstructured":"Kim JH, Kim MJ, Kang JK, Lee SA. Vasogenic edema in a case of hypercalcemia-induced posterior reversible encephalopathy. Eur Neurol. 2005, 53:160-2. 10.1159\/000086127","journal-title":"Eur Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-002-0895-x","article-title":"Posterior reversible encephalopathy syndrome due to severe hypercalcemia","volume":"249","author":"Kastrup O","year":"2002","unstructured":"Kastrup O, Maschke M, Wanke I, Diener HC. Posterior reversible encephalopathy syndrome due to severe hypercalcemia. J Neurol. 2002, 249:1563-6. 10.1007\/s00415-002-0895-x","journal-title":"J Neurol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.06.025","article-title":"Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy","volume":"63","author":"Reagan P","year":"2014","unstructured":"Reagan P, Pani A, Rosner MH. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy. Am J Kidney Dis. 2014, 63:141-7. 10.1053\/j.ajkd.2013.06.025","journal-title":"Am J Kidney Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0094","article-title":"Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA","volume":"8","author":"Ren J","year":"2019","unstructured":"Ren J, Asche CV, Shou Y, Galaznik A. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. J Comp Eff Res. 2019, 8:393-402. 10.2217\/cer-2018-0094","journal-title":"J Comp Eff Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0490","article-title":"Direct costs associated with relapsed diffuse large B-cell lymphoma therapies","volume":"24","author":"Purdum A","year":"2019","unstructured":"Purdum A, Tieu R, Reddy SR, Broder MS. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist. 2019, 24:1229-36. 10.1634\/theoncologist.2018-0490","journal-title":"Oncologist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/222354-assessing-the-impact-of-comorbid-hypercalcemia-on-inpatient-outcomes-of-patients-with-diffuse-large-b-cell-lymphoma-during-admission-for-chemotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T16:59:35Z","timestamp":1708707575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/222354-assessing-the-impact-of-comorbid-hypercalcemia-on-inpatient-outcomes-of-patients-with-diffuse-large-b-cell-lymphoma-during-admission-for-chemotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.54769","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,23]]}}}